There have been recent rapid advancements in the science of oncology with greater understanding of the biology of cancer and new therapeutic targets are being identified which hold the promise of targetted therapy for cancer. Behind the big pharma companies such as J&J and Novartis are the smaller biotech copmanies which are the originators of these new medications. So heres an insiders assessment of the biotechs developing exciting new drugs in oncology which are set to boom in 2013:
No.1 BTG (UK: BTG) - Zytiga (Abiraterone Acetate), licensed to J&J (JNJ)
Varisolve
No. 2 Medivation (MDVN) - Xtandi (Enxalutamide), partnered with Astellas
No. 3 Exelixis (EXEL) - Cometriq (Cabozantinib) FDA approved for thyroid cancer.
Potent anti-metastatic agent, set to be a blockbuster
Clinical trials for prostate, breast, lung, kidney, and brain cancer
No. 4 Pharmacyclics (PCYC) - Ibrutinb for CLL and MCL, partnered with J&J, FDA breakthrough status.
No. 5 Astex (ASTX) - 6 Drugs in clinical trials, partnered Novartis and J&J.
No. 6 Array (ARRY) - 5 Drugs in clinical trials, several partners.
No. 7 Curis (CRIS) - Hedgehog Pathway Inhibitor, partnered Roche.
No.8 Aveo (AVEO) - Tivozanib for kidney cancer, FDA submitted, partnered Astellas.
No. 9 Cleveland Biolabs (CBLI) - Curaxins, apoptosis.
No. 10 Spectrum Pharmaceuticals (SPPI) - Zevalin targetted radiotherapy
No comments:
Post a Comment